| | | | | | | | | | | | | | | | |
| |
 | Issue Date FY: 2025 ( Subtotal = $78,142,716 ) (Continued on the next page) |
| 2025 | 2025 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA255721 | Biology and novel therapy of AML expressing somatic or germline mutant RUNX1 | 000 | 5 | NIH | 11/13/2024 | $447,219 |
| 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA247862 | Replication stress response defects predict and enhance immune checkpoint therapy response in triple negative breast cancer | 000 | 5 | NIH | 12/27/2024 | $332,463 |
| 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA264992 | Establishing the clinical utility of a consensus DSC-MRI Protocol | 001 | 4 | NIH | 5/22/2025 | $55,614 |
| 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA264992 | Establishing the clinical utility of a consensus DSC-MRI Protocol | 000 | 4 | NIH | 3/13/2025 | $500,546 |
| 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA207295 | DNA damaging therapy and immune response in small cell lung cancer subtypes | 000 | 9 | NIH | 3/5/2025 | $348,525 |
| 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA207295 | DNA damaging therapy and immune response in small cell lung cancer subtypes | 001 | 9 | NIH | 5/22/2025 | $38,725 |
| 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA295834 | Endogenous Circular RNAs limit abemaciclib anti tumor immune responses | 000 | 1 | NIH | 3/17/2025 | $567,059 |
| 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01HL158796 | New data science approaches to visualize and understand the impact of the microbiome on risk of graft-versus-host disease | 000 | 4 | NIH | 2/19/2025 | $243,000 |
| 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01EB034665 | Single-use Microfluidic Device for Radiopharmaceutical Production | 001 | 1 | NIH | 4/2/2025 | $0 |
| 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA287279 | Deciphering the structural determinants of response and resistance to HER2-targeted antibody-drug conjugates and tyrosine kinase inhibitors for HER2-mutant Non-Small Cell Lung Cancer | 000 | 1 | NIH | 3/19/2025 | $695,004 |
| 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01EB034665 | Single-use Microfluidic Device for Radiopharmaceutical Production | 000 | 1 | NIH | 2/25/2025 | $574,632 |
| 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01DE030875 | Functional roles of GOF TP53 mutations in metastasis and immunosuppression of head and neck cancers | 001 | 4 | NIH | 5/7/2025 | $55,614 |
| 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01DE030875 | Functional roles of GOF TP53 mutations in metastasis and immunosuppression of head and neck cancers | 000 | 4 | NIH | 3/10/2025 | $500,532 |
| 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA288617 | TROP2-Directed CAR-NK Cells for the Immunotherapy of Pancreatic Cancer | 001 | 2 | NIH | 5/23/2025 | $37,057 |
| 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA288617 | TROP2-Directed CAR-NK Cells for the Immunotherapy of Pancreatic Cancer | 000 | 2 | NIH | 3/3/2025 | $333,518 |
| 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | K99CA296780 | The role of oral microbiota in metastatic brain tumors | 000 | 1 | NIH | 3/10/2025 | $112,026 |
| 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01AG067419 | Alzheimer's Disease Pathology in a Primate Model | 000 | 5 | NIH | 2/14/2025 | $646,905 |
| 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21CA288901 | Proteomics-driven precision molecular mapping of patient tumors to preclinical models in lung cancer | 000 | 1 | NIH | 3/11/2025 | $244,228 |
| 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA299972 | Deregulation of Sulfatide Synthesis in the Development and Progression of Pancreatic Cancer Precursor Lesions | 000 | 1 | NIH | 3/1/2025 | $616,495 |
| 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA258788 | A Comprehensive Clinical fMRI Software Solution to Enable Mapping of Critical Functional Networks and Cerebrovascular Reactivity in the Brain | 001 | 4 | NIH | 5/22/2025 | $54,957 |
| 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA258788 | A Comprehensive Clinical fMRI Software Solution to Enable Mapping of Critical Functional Networks and Cerebrovascular Reactivity in the Brain | 000 | 4 | NIH | 2/14/2025 | $494,624 |
| 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA301555 | Delivery optimization of a transarterial ablative therapy | 000 | 1 | NIH | 3/11/2025 | $536,836 |
| 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01GM152497 | Computational toolkit for robust detection of genomic variation in human leukocyte antigen genes | 000 | 2 | NIH | 3/5/2025 | $263,340 |
| 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA256006 | Glioma therapy with oncolytic adenoviruses and immunometabolic adjuvants | 002 | 5 | NIH | 5/22/2025 | $37,057 |
| 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA256006 | Glioma therapy with oncolytic adenoviruses and immunometabolic adjuvants | 001 | 5 | NIH | 5/2/2025 | $0 |
| 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA256006 | Glioma therapy with oncolytic adenoviruses and immunometabolic adjuvants | 000 | 5 | NIH | 2/18/2025 | $333,518 |
| 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R61NS140684 | Development and validation of a tumor-bearing model of oxaliplatin-induced neuropathy | 001 | 1 | NIH | 4/9/2025 | $408,277 |
| 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R61NS140684 | Development and validation of a tumor-bearing model of oxaliplatin-induced neuropathy | 001 | 1 | NIH | 4/9/2025 | -$408,277 |
| 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R61NS140684 | Development and validation of a tumor-bearing model of oxaliplatin-induced neuropathy | 000 | 1 | NIH | 1/31/2025 | $408,277 |
| 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01AT012375 | Multi-site feasibility and acceptability of a faith-based mind-body intervention in Black adults | 001 | 3 | NIH | 3/19/2025 | $0 |
| 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01AT012375 | Multi-site feasibility and acceptability of a faith-based mind-body intervention in Black adults | 000 | 3 | NIH | 1/29/2025 | $497,585 |
| 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA256848 | Determining the optimal ion and fractionation scheme for the treatment of GBM in a comprehensive human organoid model | 000 | 5 | NIH | 2/14/2025 | $412,116 |
| 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA243142 | Regulation of tumor recurrence by stress activated neutrophils | 001 | 6 | NIH | 5/22/2025 | $50,072 |
| 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA243142 | Regulation of tumor recurrence by stress activated neutrophils | 000 | 6 | NIH | 1/28/2025 | $450,650 |
| 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA278938 | Comparative Effectiveness of Sequential Pharmacotherapeutic Strategies and Virtually Delivered Treatment to Optimize Smoking Cessation | 001 | 2 | NIH | 5/30/2025 | $91,110 |
| 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA278938 | Comparative Effectiveness of Sequential Pharmacotherapeutic Strategies and Virtually Delivered Treatment to Optimize Smoking Cessation | 000 | 2 | NIH | 12/23/2024 | $819,991 |
| 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | U01CA275886 | Identifying and targeting collateral lethal vulnerabilities in cancers | 002 | 3 | NIH | 5/22/2025 | $96,704 |
| 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R37CA288448 | Mechanisms of Hyperprogression to Immunotherapy in SMARCB1-Deficient Renal Malignancies | 001 | 2 | NIH | 5/22/2025 | $67,229 |
| 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | U01CA275886 | Identifying and targeting collateral lethal vulnerabilities in cancers | 001 | 3 | NIH | 3/12/2025 | $870,334 |
| 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R37CA288448 | Mechanisms of Hyperprogression to Immunotherapy in SMARCB1-Deficient Renal Malignancies | 000 | 2 | NIH | 3/3/2025 | $605,071 |
| 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R37CA271187 | Optimizing Personalized Screening and Diagnostic Decisions for Lung Cancer Based on Dynamic Risk Assessment and Life Expectancy | 000 | 4 | NIH | 4/23/2025 | $437,952 |
| 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01MD017999 | Health equity in fertility specialty care among cancer survivors | 001 | 3 | NIH | 4/26/2025 | $49,713 |
| 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA299696 | Decoding the co-evolution of cancer subclones and their ecosystem in TNBC multi-organ metastasis | 000 | 1 | NIH | 3/12/2025 | $676,584 |
| 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA269489 | Molecular Mechanisms of Bladder Cancer Immunometabolism | 001 | 3 | NIH | 5/22/2025 | $49,385 |
| 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA269489 | Molecular Mechanisms of Bladder Cancer Immunometabolism | 000 | 3 | NIH | 3/7/2025 | $444,485 |
| 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA269646 | Targeting ferroptosis in cancer therapy | 001 | 3 | NIH | 5/22/2025 | $49,400 |
| 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA269646 | Targeting ferroptosis in cancer therapy | 000 | 3 | NIH | 2/13/2025 | $444,596 |
| 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA258917 | Mitochondrial heterogeneity as the origin of chemoresistance in pancreatic cancer | 001 | 5 | NIH | 5/23/2025 | $46,003 |
| 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA258917 | Mitochondrial heterogeneity as the origin of chemoresistance in pancreatic cancer | 000 | 5 | NIH | 3/7/2025 | $414,028 |
|